Drug profile

The FDA adverse-event record for Monoclonal Antibody Treatment

32 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Monoclonal Antibody Treatment. See the species affected, top reactions, and outcomes below.

32
adverse-event reports
3.1%
death-coded share
Dog
most-reported species
7
Lack of efficacy - NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
32
Total Reports
1
Deaths Reported
3.1%
Death Rate

Active Ingredients

Monoclonal Antibody Treatment

Administration Routes

UnknownSubcutaneousParenteral

Species Affected

Dog 32

Most Affected Breeds

Beagle 3
Chihuahua 3
Boxer (German Boxer) 3
Shih Tzu 2
Shepherd Dog - German 2
Pug 2
Terrier - Yorkshire 2
Terrier - Boston 2
Retriever - Labrador 2
Pit Bull 2

Most Reported Reactions

Lack of efficacy - NOS 7
Vomiting 6
Panting 6
Abnormal movement NOS 4
Corneal ulcer 4
Diarrhoea 4
Decreased appetite 4
Lethargy (see also Central nervous system depression in Neurological) 4
Behavioural disorder NOS 3
Lethargy (see also Central nervous system depression in 'Neurological') 3
Abdominal cavity haemorrhage 3
Skin inflammation NOS 3

Outcome Breakdown

Outcome Unknown
19 (59.4%)
Recovered/Normal
10 (31.3%)
Ongoing
2 (6.3%)
Died
1 (3.1%)

Monoclonal Antibody Treatment Adverse Event Insights

32 reports name Monoclonal Antibody Treatment; 1 recorded a death outcome (3.1% of reported events, not a population-level mortality rate). Active ingredient: Monoclonal Antibody Treatment. Administration routes: Unknown, Subcutaneous, Parenteral.

By species: Dog (32 reports). By breed: Beagle (3), Chihuahua (3), Boxer (German Boxer) (3).

Leading clinical signs: Lack of efficacy - NOS (7), Vomiting (6), Panting (6), Abnormal movement NOS (4). Outcome, 32 coded reports: Outcome Unknown leads at 59.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.